MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
5.71
+0.03
+0.53%
Pre Market: 5.84 +0.13 +2.28% 04:34 05/14 EDT
OPEN
5.81
PREV CLOSE
5.68
HIGH
5.93
LOW
5.53
VOLUME
955
TURNOVER
1.64M
52 WEEK HIGH
7.54
52 WEEK LOW
4.000
MARKET CAP
324.80M
P/E (TTM)
5.31
1D
5D
1M
3M
1Y
5Y
1D
Abeona Therapeutics Signals Strong Early ZEVASKYN Launch
TipRanks · 9h ago
Abeona (ABEO) Q1 2026 Earnings Transcript
NASDAQ · 13h ago
Analysts Are Bullish on These Healthcare Stocks: Abeona Therapeutics (ABEO), Protara Therapeutics (TARA)
TipRanks · 17h ago
Abeona Q1 FY26 net product revenue more than doubled to $8.7 million; SG&A rises to $19.5 million
PUBT · 18h ago
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
Benzinga · 20h ago
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
Benzinga · 21h ago
Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)
TipRanks · 22h ago
Abeona Therapeutics posts smaller-than-expected Q1 loss per share
Reuters · 22h ago
More
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.